News headlines about Ocular Therapeutix (NASDAQ:OCUL) have trended positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocular Therapeutix earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.1863608611533 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Equities Analysts Issue Forecasts for Ocular Therapeutix Inc’s FY2018 Earnings (OCUL) (americanbankingnews.com)
- Ocular Therapeutix, Inc. (OCUL) – Analyst rating score stands at 1.90 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Is the Stock Safe to Invest? – Nasdaq Journal (nasdaqjournal.com)
- Ocular Therapeutix (OCUL) Raised to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Ocular Therapeutix (OCUL) Earns “Buy” Rating from BTIG Research (americanbankingnews.com)
Shares of Ocular Therapeutix (NASDAQ OCUL) traded down $0.15 during trading hours on Wednesday, hitting $6.18. The stock had a trading volume of 203,501 shares, compared to its average volume of 507,400. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.23 and a quick ratio of 3.22. Ocular Therapeutix has a one year low of $3.30 and a one year high of $11.79. The firm has a market capitalization of $237.46, a price-to-earnings ratio of -2.83 and a beta of 1.51.
A number of research firms have recently weighed in on OCUL. Zacks Investment Research raised Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a report on Tuesday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $22.00 price target on shares of Ocular Therapeutix in a research note on Thursday, March 8th. BTIG Research upgraded Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research report on Friday, January 19th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Ocular Therapeutix in a report on Friday, March 9th. Finally, ValuEngine cut Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Ocular Therapeutix has an average rating of “Buy” and an average target price of $11.92.
TRADEMARK VIOLATION WARNING: This story was originally posted by BBNS and is the sole property of of BBNS. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://baseballnewssource.com/2018/03/14/positive-media-coverage-somewhat-unlikely-to-impact-ocular-therapeutix-ocul-share-price/1925231.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.